Coding Bio specializes in developing advanced immunotherapies for cancer treatment by leveraging high-throughput screening and machine learning technologies. Their approach involves testing millions of modular protein candidates directly in living cells, which allows for rapid generation and evaluation of data that is crucial for identifying optimal therapy designs. This high-throughput lab capability enables Coding Bio to produce previously inaccessible data that informs their machine learning platform, enhancing the understanding of immune responses beyond traditional protein binding methods.

The company's machine learning platform plays a pivotal role in analyzing protein structures to uncover patterns that influence therapy quality. By iterating on various designs, Coding Bio aims to maximize therapeutic performance while connecting data across different disease states to deepen insights into the immune system. This integration of data and machine learning facilitates the engineering of immunotherapies with unprecedented speed, allowing for quicker transitions from development to clinical application, ultimately improving the chances of successful patient outcomes.

United Kingdom

Coding Bio unites a high throughput wet lab and ML platform to screen, build, and deliver fully-assembled modular therapies like CARs and BiTEs in only months.

Coding Bio

Company Details